Pharmacology & ToxicologybioRxivPreprint
Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor
Ed Griffen, D. Fearon, Briana Lynn McGovern…·Annette von Delft
This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.
5 citations